Fig. 2.
Fig. 2. Donor chimerism after myeloablative and nonmyeloablative transplantation. / Peripheral blood was obtained from patients on days +14, +28, +42, +56, +100, and +180 after transplantation. Subpopulations were purified by magnetic bead sorting and analyzed for percentage of donor origin by STR analysis. The graphs show the mean percentage of donor chimerism and SD for each cell population studied. (A-D) Mean donor chimerism for 5 patients that underwent myeloablative allogeneic HCT. (A-E) Mean donor chimerism for 8 patients that underwent nonmyeloablative allogeneic HCT. Cell subsets analyzed were dendritic cells (A,E), B lymphocytes (B,F), T lymphocytes (C,G), and myelocytes and monocytes (D,H).

Donor chimerism after myeloablative and nonmyeloablative transplantation.

Peripheral blood was obtained from patients on days +14, +28, +42, +56, +100, and +180 after transplantation. Subpopulations were purified by magnetic bead sorting and analyzed for percentage of donor origin by STR analysis. The graphs show the mean percentage of donor chimerism and SD for each cell population studied. (A-D) Mean donor chimerism for 5 patients that underwent myeloablative allogeneic HCT. (A-E) Mean donor chimerism for 8 patients that underwent nonmyeloablative allogeneic HCT. Cell subsets analyzed were dendritic cells (A,E), B lymphocytes (B,F), T lymphocytes (C,G), and myelocytes and monocytes (D,H).

Close Modal

or Create an Account

Close Modal
Close Modal